Connect with us

Published

on

Ashley Capoot wearing a CGM.

Ashley Capoot | CNBC

As it turns out, exercise is good for you. So is sleep, and unfortunately, so are vegetables. 

I’ve heard these health adages hundreds of times before, but they truly began to hit home for me this winter as I tested out a metabolic health platform from the startup Signos. In short, the company offers a subscription service that includes a small continuous glucose monitor (CGM), which you stick on your arm or abdomen, that sends that data to the Signos app which, in turn, aims to help you lose weight by keeping track of your blood sugar.

The subscription price varies depending on the plan you pick. A one-month plan starts at $449, but a 6-month plan starts at about $143 a month if you pay upfront. But services like this, once reserved for diabetics, may soon offer a whole new revenue stream for health companies. Dexcom, for example, recently received FDA clearance for its over-the-counter Stelo product, expected to launch this summer. Meanwhile, Signos competes with other firms like NutriSense, Veri and Levels.

I wanted to get a first-hand understanding of what these glucose monitors are like, so I gave Signos’ latest system, which uses a Dexcom G7 monitor, a try. Here’s what I learned.

Signos

Founded in 2018, Signos uses continuous glucose monitors, or CGMs, and an artificial intelligence-powered app to help people better understand their metabolisms. The company gives users personalized insights into how their bodies respond to specific foods and when they should exercise to get the best results for weight loss. 

Glucose is a type of sugar we receive from food, and it’s the body’s main source of energy. A CGM is a small sensor that pokes through the skin to track an individual’s blood glucose levels, or blood sugar levels, in real-time. The sensor is usually worn on the upper arm or abdomen, and it can wirelessly transmit data to a smartphone. 

CGMs are primarily used by people with diabetes since they can help patients get alerted to emergencies. But Signos’ CGM system is meant for average consumers, so it is not intended for diabetes management. Other companies like Abbott Laboratories are also launching consumer-facing CGM systems in the U.S. this year. 

Signos’ platform teaches users how their daily habits like diet, hydration, exercise, stress and sleep affect their glucose and can cause it to spike. 

Glucose spikes occur when the amount of sugar present in the bloodstream rapidly increases. This often happens after eating. In the short term, spikes can cause feelings of lethargy and fatigue, but high blood sugar can lead to more serious health problems like diabetes, heart disease and kidney disease over time, according to the Centers for Disease Control and Prevention

Everyone’s glucose levels are variable, so spikes and dips are inevitable, but Signos aims to help people reduce the intensity and frequency of their spikes. The company says that maintaining relatively stable glucose levels can help people improve the health of their metabolism, lose weight and ultimately reduce the risk of chronic disease. 

Getting set up

Woman with Signos wearable and app

Source: Signos

To get started with Signos, I had to take a quick questionnaire that asked me for some basic biological information and details about my medical history. I submitted my answers for review by an independent physician, and my CGM prescription was approved and began processing for shipment a few hours later.

After a couple of days, my kit arrived in a brown Signos box. It includes an instruction manual, the CGMs, alcohol wipes and athletic patches to put over the CGM once it’s applied. I followed the instructions in the manual and downloaded the Signos app, which prompted me to set up accounts with Signos and the CGM company Dexcom

Dexcom makes the CGMs that Signos uses, though Dexcom’s products are exclusively designed for patients diagnosed with diabetes. Signos is using Dexcom’s CGMs as part of a clinical study approved by an institutional review board designated by the U.S. Food and Drug Administration, which monitors biomedical research involving real people, Sharam Fouladgar-Mercer, Signos’ co-founder and CEO, told CNBC in October. 

Dexcom Ventures also backs Signos as an investor, and the firm participated in the $20 million funding round that Signos announced last fall.  

Signos’ platform works with Dexcom’s G6 CGM and the newer G7 CGM. I tested the platform using the G7, which Signos launched in January. The G6 and the G7 sensors last for 10 days, and I went through three G7s during my trial. 

Ashley Capoot wearing a CGM.

Ashley Capoot | CNBC

Once I had set up my accounts, it was time to put on my first sensor, which I was nervous about.

I’m generally fine around needles, though I tend to look away if I have to get a shot at the doctor’s office. The CGM’s needle is small – it looks like someone clicked a mechanical pencil a few times, for comparison – but I can’t say I was excited to stick it into my arm. 

Much to my relief, applying the sensor is easy and painless.

The Signos app walked me through the process step by step, offering a one-minute video and a series of GIFs I could watch. I cleaned the back of my left arm with an alcohol wipe, placed the applicator there, pressed the button on the applicator and popped the CGM, needle and all, right onto my arm. The G7 is white, about the size of a quarter, and maybe half an inch thick.  

I paired the CGM to the Signos app by enabling Bluetooth and scanning the corresponding QR code on my applicator. Once the CGM was applied and paired to my app, I put a purple athletic patch on top to help protect the sensor from tugging, sweat and water. 

It took the sensor about 30 minutes to adjust to my body before it was warmed up and ready to go.

What’s good

I was worried that the CGM would be painful or cumbersome, but I forgot about it often, and it’s easy to wear normal clothes and jackets over it, even if they have tight sleeves. 

I experienced some sensitivity for a couple days when sleeping on my left side, particularly after changing out the sensor. My upper arm felt a little tender, like there was a light bruise. However, I chose to wear the CGM in the same place on my left arm each time, and I think I could have avoided that sensitivity if I had switched between my left arm and my right arm.

I had never seen or interpreted glucose data before, and I thought the Signos platform did a nice job explaining concepts and breaking them down. The app led me through a series of short articles and activities to get started, like how to log my meals and exercise. 

It also introduced me to the concept of my “optimal glucose range,” which is where Signos wants you to try and keep your glucose levels. Signos starts by setting the upper bound of the range at 120 mg/dL, and the lower bound at 80 mg/dL, but the app’s algorithm adjusts it based on your body’s patterns. My upper bound was eventually adjusted to 126 mg/dL, for instance. 

When you look at the Signos home page, you can see your real-time glucose reading, your glucose level graph (which includes a shaded area to indicate your optimal range), and the percentage of time you’ve spent in the range each day. This could be particularly beneficial for folks who may be prediabetic and want to keep an eye on their levels over time.

Once I got the hang of the basics, Signos prompted me with more activities and articles that helped me experiment and deepen my understanding of my blood sugar. For instance, one activity encouraged me to try exercising right after a meal, and when I did, I saw it drastically reduced the spike I was experiencing. 

Another activity had me try and guess what I thought my glucose levels were at different points throughout the day. I was surprised how quickly I began to understand the correlation between how I was feeling and my current reading. You can skip activities if you don’t want to do them, but on the whole, I found them interesting and useful.  

Signos also has registered dieticians on staff, and users can ask them questions via chat, email or through a phone consultation. I set up a meeting after my first week wearing a CGM, and I found it very helpful. I asked a bunch of questions about my data and the Signos app itself, and I also got some tips about what to try and work on next.

The Signos platform.

I knew the experience would be personalized, but I don’t think I’ve ever had this much specific insight into what is happening in my body. I found it fascinating to see how I responded to different foods, and there were some surprises.

I frequently eat instant oatmeal for breakfast, for example, and have always thought of it as a relatively healthy meal. But in actuality, I learned oatmeal causes my glucose to spike significantly. On Feb. 9, oatmeal raised my levels from 88 mg/dL to 167 mg/dL. So while it may be a great breakfast for some people, oatmeal isn’t necessarily the best choice for me. 

I was less surprised by my reactions to many other foods, but I still found it valuable to reinforce these concepts with data. Processed foods like chips and sweets caused large spikes in my levels, but fruits, vegetables and protein-rich meals had a much more gradual impact. I eat greek yogurt as a snack a lot, for instance, and I found that it hardly caused my levels to spike.  

It felt powerful to see how my body responded to nutritious food and it definitely made me more conscious of the choices I was making.   

Ashley Capoot wearing a CGM.

Ashley Capoot | CNBC

As it turns out, spikes in your blood sugar can be caused by a whole lot more than just food. That was news to me. In addition to logging meals and exercise, the Signos app has a “Tags” feature where you can write notes and select from a list of more than 60 different possible spike-causing culprits. Some of the options include stress, travel, medication, sickness, crying and even a hot shower. 

I learned that my glucose tends to spike while I’m writing a breaking news story (who knew!), and I spend less time in my optimal range when I’m feeling tired. I had a particularly stressful week at work in January, and looking back at my readings, I can definitely tell. 

I found it helpful to visualize how all sorts of different factors, some within my control and some not, could impact my blood sugar. It really drives home the idea that you are affected by the world around you.     

And for bonus points, the CGM is a great conversation starter. 

I found that my friends, family and colleagues were really interested in the device and what I was learning from it. Since it’s not all that common for the average person to wear CGMs yet, I think there was an element of novelty there. 

Finally, it’s easy to take off the CGM when it expires. After the 10 days are up, you simply grab the adhesive and peel it off like a sticker.  

What’s bad

Signos’ user interface is easy to use, but some features were more intuitive than others. 

It took me a few days to learn how to input my sleep, for instance, because I couldn’t figure out how to log the hours correctly. It was also hard to gauge how much detail to use when logging my meals, as I tended to keep my entries to just a few words. I might have gotten more specific insights and fine-tuned my algorithm further if I had more guidance there. 

Additionally, it wasn’t always possible for me to engage with the platform’s alerts and activities, particularly during the work day. 

After eating a meal, I would often get a “Fast Rise” notification from my Signos app, which indicates that a glucose spike is occurring. The notification encourages users to engage in 20 to 30 minutes of “brisk walking” or 10 to 15 minutes of plyometrics, a form of high-intensity exercise, to help reduce the spike. I work in-person at CNBC’s newsroom three days a week, so this often wasn’t realistic for me to do. 

I asked about this notification when I met with the Signos dietitian, and she told me that any movement is beneficial, even if it’s just a quick walk up or down a flight of stairs. I tried to make sure to take a lap around the newsroom once I learned that, but I think it would have been helpful to know upfront, too. 

A “Fast Rise” notification on Signos.

Subscriptions to Signos are expensive, and for many users, CGMs are not covered by insurance yet. Customers who sign up for Signos can choose a one-month, three-month or six-month plan.

The steep price tag is definitely worth considering. According to its website, Signos said users who have been diagnosed with type 2 diabetes may be able to get the cost of the CGM covered by their insurer. But users who do not have type 2 diabetes may be out of luck. 

The company said some people may be able to use their Health Savings Account reimbursement funds to cover the Signos, but that it “is not responsible for reimbursement in any capacity,” according to the site.  

In other words, users who want to try and reduce the costs of the platform have to try and figure it out themselves. 

I also found myself checking the Signos app frequently, almost like it became another form of social media. This gave me some pause. 

I have been fortunate to have had a relatively positive relationship with food throughout my life, and I’m also not someone who experiences much health anxiety. Even so, I tried to be very conscious of my mindset and attitude toward the Signos platform. I treated Signos like a tool and a learning experience, and I really didn’t want to put too much emphasis on the numbers. 

I knew that approach would be best for me, and it worked well for the most part. However, I did catch myself feeling guilty about large spikes on a few occasions. 

As I noticed those feelings, and how often I was checking the app, I felt like it was pretty easy to see how the platform could end up being harmful for some users’ mental health, particularly if they’ve struggled with body image or eating disorders. 

Signos said all prospective members are asked about their medical history, including disordered eating, in their initial medical questionnaire. If someone is actively experiencing or in recovery from an eating disorder, Signos said the independent physician would not approve them for participation in the Signos program.

The company said it does not recommend any specific eating style, and there are metabolic health coaches on staff to help check in with users about how they feel. 

As with most things, I think trusting yourself is key here. If you don’t think accessing your metabolic data would be good for your mental health, then using a CGM is probably not a great idea. You can also always check in with your doctor to decide if the technology is right for you. 

Takeaways

The Signos experience really depends on you, the user. 

The app isn’t going to do the learning or make lifestyle changes for you, so if you aren’t willing to take the time to log your meals and complete activities, chances are you won’t get much out of the platform. 

As a young and relatively healthy individual, I wasn’t sure what to expect from Signos, but I learned a lot about how my body responds to my diet, sleep, exercise and stress. The CGM is like a little window into what goes on beneath the skin, and I think it’s easy to see why it’s a valuable tool. After just one month of use, I have a deeper understanding of why I feel sleepy, lethargic or energized.

I wouldn’t be surprised if I return to CGM systems at different stages of my life to better understand how I am responding to my nutrition and the world around me.  

Continue Reading

Technology

Getty Images stock pops 19% on deal with Perplexity AI

Published

on

By

Getty Images stock pops 19% on deal with Perplexity AI

The Perplexity application appears on a smartphone screen in this photo illustration in Athens, Greece, on October 2, 2025.

Nikolas Kokovlis | Nurphoto | Getty Images

Shares of Getty Images soared 19% on Friday after the company announced that it struck a multi‑year licensing agreement with Perplexity AI.

Perplexity will be able to display creative and editorial content from Getty Images through its AI-powered search tools as part of the deal, according to a release. The startup will also improve how it displays imagery on its platform by adding image credits and links to the source.

“Partnerships such as this support AI platforms to increase the quality and accuracy of information delivered to consumers, ultimately building a more engaging and reliable experience,” Nick Unsworth, vice president of strategic development at Getty Images, said in a statement.

The financial terms of the agreement were not disclosed.

Read more CNBC tech news

Perplexity CEO Aravind Srinivas: Comet browser is meant to be 'a true personal assistant'

Continue Reading

Technology

Amazon’s stock soars 12% on third-quarter beat and increased spending guidance

Published

on

By

Amazon's stock soars 12% on third-quarter beat and increased spending guidance

Amazon CEO Andy Jassy speaks during an Amazon Devices launch event in New York City, U.S., February 26, 2025. 

Brendan Mcdermid | Reuters

Amazon shares soared 12% on Friday after the company reported an across-the-board beat for the third quarter and boosted its forecast for spending due to demand for artificial intelligence services.

Cloud was a major driver of revenue and profit growth, with sales at Amazon Web Services climbing 20% from a year earlier to $33 billion, topping expectations.

The unit generated operating income of $11.4 billion, accounting for roughly two-thirds of Amazon’s total operating profit.

Revenue in the digital advertising business, another growth engine, jumped 24% to $17.7 billion. Total sales at Amazon climbed 13% to $180.17 billion, topping the average analyst estimate of $177.8 billion, according to LSEG. Earnings per share came in at $1.95, exceeding the $1.57 average estimate.

“Amazon has a deep moat around their core businesses driven by their unmatched scale,” analysts at Pivotal Research wrote in a note after the report.

The analysts, who recommend buying the stock, said Amazon “appears to have numerous healthy organic growth opportunities driven by their high margin AWS cloud segment” and areas like advertising.

Coming into earnings, cloud was an area of key concern due to increased competition from Google and Microsoft, which also reported quarterly results this week. Google’s cloud revenue increased 34% during the third quarter, while Microsoft Azure recorded growth of 40%.

Read more CNBC tech news

Amazon’s stock was up just 1.6% for the year ahead of the report, well behind its megacap peers.

While the company remains the leading provider of cloud infrastructure technology, it’s been battling the perception that it’s missing out on a flurry of highly lucrative AI deals for cloud services.

But when it comes to spending, Amazon is ahead of its rivals.

Amazon raised its forecast for capital expenditures this year, saying it now expects to spend $125 billion in 2025, up from an earlier estimate of $118 billion. CFO Brian Olsavsky said that number will likely increase in 2026. Google, Meta and Microsoft also lifted their capex guidance, but were all below Amazon.

For the current quarter, Amazon said it expects sales to be $206 billion to $213 billion. The midpoint of the revenue outlook, $209.5 billion, topped estimates of $208 billion, according to LSEG.

While investors are cheering Amazon’s results, it’s been a tough week for a wide swath of the company’s workforce.

On Tuesday, Amazon said it will lay off 14,000 corporate employees, as part of a push to make the company leaner and less bureaucratic, so it can move faster. More cuts are expected soon, and Jassy said it’s not “financially driven” or due to AI, “right now, at least.”

“It really, it’s culture,” Jassy said. “If you grow as fast as we did for several years, you know, the size of the businesses, the number of people, the number of locations, the types of businesses you’re in, you end up with a lot more people than what you had before, and you end up with a lot more layers.”

The company finished the quarter with about 1.58 million employees, which was a 2% increase from the year-ago period.

Sales in Amazon’s core online stores unit posted growth of 10% during the quarter, which includes the results of its Prime Day discount event in July.

WATCH: Apple will outperform Amazon

Apple will outperform Amazon from tomorrow to end of year, says Deepwater's Gene Munster

Continue Reading

Technology

Tech’s $380 billion splurge: This quarter’s winners and losers of the AI spending boom

Published

on

By

Tech's 0 billion splurge: This quarter's winners and losers of the AI spending boom

Mark Zuckerberg, chief executive officer of Meta Platforms Inc., during the Meta Connect event in Menlo Park, California, US, on Wednesday, Sept. 17, 2025.

David Paul Morris | Bloomberg | Getty Images

Tech’s internet giants have made it through earnings season, and they offered a consistent message to Wall Street: Artificial intelligence investments are only getting bigger.

Alphabet, Meta, Microsoft and Amazon each lifted their guidance for capital expenditures and now collectively expect that number to reach more than $380 billion this year.

Microsoft’s forecast was for fiscal 2026, which ends in June.

The companies are racing to build out infrastructure for what they say is virtually limitless demand for AI services.

Meanwhile, a growing number of skeptics are voicing concerns that these historic spending levels are fueling a bubble, and they’re questioning whether there’s sufficient energy and resources to ever turn lofty AI promises into reality.

As big as the spending projections were this week, they look pedestrian when compared with OpenAI, which has announced roughly $1 trillion worth of infrastructure deals of late with partners including Nvidia, Oracle and Broadcom.

Investor reactions to the megacap reports were mixed.

Amazon saw its stock soar after the company beat on earnings and revenue, and said capex this year will be about $125 billion, up from a prior forecast of $118 billion.

“We’ll continue to make significant investments, especially in AI,” finance chief Brian Olsavsky said on the earnings call, adding that the number will grow in 2026. “We believe it to be a massive opportunity with the potential for strong returns on invested capital over the long term.”

Amazon beats on earnings and revenue with strong cloud rebound and bullish Q4 guidance

Investors also cheered Alphabet, which reported an earnings beat and boosted its capex forecast for this year to between $91 billion and $93 billion from a prior range of $75 billion to $85 billion. The stock rose 2.5% on Thursday.

But Microsoft shares fell about 3% even though the software company’s results exceeded estimates.

CFO Amy Hood said on the earnings call that capex growth would accelerate in fiscal 2026, which started in July, after the company had previously said growth would slow. Capex rose 45% to $64.55 billion last fiscal year, suggesting a minimum of about $94 billion in 2026. That number is significantly higher when including leases.

Meta’s stock was hit harder, plummeting 11% on Thursday, its steepest drop in three years, despite an across-the-board beat. The company narrowed its capex guidance to between $70 billion and $72 billion, from a prior range of $66 billion to $72 billion.

‘Unknown revenue opportunity’

Unlike Amazon, Microsoft and Google, Meta doesn’t have a cloud service and lacks a clear revenue story that’s tied to its AI investments.

Meta says its benefits from AI come elsewhere, namely improved performance in its core digital ads business from better targeting.

Still, analysts at Oppenheimer downgraded the stock to the equivalent of a hold from buy, citing an “unknown revenue opportunity” in what the company is calling superintelligence, and said investors will struggle with “aggressive revenue growth offset by high spending.”

Google, by contrast, has “predictable earnings,” the analysts wrote.

Meta CEO Mark Zuckerberg announced in June the creation of the company’s Superintelligence Labs, and said it would be led by some of his company’s costly high-profile hires, including Scale AI ex-CEO Alexandr Wang and former GitHub CEO Nat Friedman.

The lab would house the company’s various teams working on foundation models, Zuckerberg wrote in a memo at the time.

“I’m optimistic that this new influx of talent and parallel approach to model development will set us up to deliver on the promise of personal superintelligence for everyone,” Zuckerberg wrote.

But the Oppenheimer analysts said it’s an approach that “mirrors” the company’s metaverse spending in 2021 and 2022, when Zuckerberg was declaring that platform to be the future of computing.

Meta is still burning billions of dollars a quarter on its investments in augmented reality. The company said in its earnings report that its Reality Labs unit lost $4.4 billion in the quarter on $470 million in revenue.

‘No end in sight’

Microsoft CEO Satya Nadella speaks at Microsoft Build AI Day in Jakarta, Indonesia, on April 30, 2024.

Adek Berry | AFP | Getty Images

For the other hyperscalers, investments in AI largely tie into their cloud infrastructure businesses, even as they’re using AI companywide.

Within cloud computing, Amazon Web Services is still bigger than Microsoft Azure or Google Cloud, but it’s growing more slowly than its rivals.

AWS reported revenue growth in the third quarter of 20% to $33 billion. Microsoft said Azure revenue increased by 40%, while Google’s cloud sales rose 34% to $15.15 billion.

Analysts at Cantor said that clouds with “expansive service stacks like Microsoft” are in a position to benefit from this “heightened phase of AI infrastructure build out.”

They recommend buying the stock, but see reasons to be worried about the spending forecast. The analysts said that total capex, which includes capital leases, is poised to reach $140 billion this year, up 58% from a year earlier and triple the figure from 2024.

That number “is reflective of strong demand on the positive side, but remains a concern as there appears no end in sight,” the analysts wrote.

WATCH: Meta capex doesn’t necessarily result in ROI

Kunst: Meta has a lot of capex that doesn't necessarily translate to a return on investment

Read more CNBC tech news

Continue Reading

Trending